PRESENTATION ON SUN PHARMA RANBAXY AND MANKIND PHARMA

•Thank youPresented by

Abhishek

Abhijit

Anirban

manikandan

OHM LABORATORIES TO LAUNCH VALSARTAN TABLETS JUNE .27. 2014

• Receives first-to-file FDA approval, with

180-day marketing exclusivity for generic version in the treatment of hypertension and heart failure

• New Brunswick: NJ– Ohm Laboratories, Inc. (Ohm), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.

• Ranbaxy Laboratories Limited, India’s leading pharmaceutical company, is an integrated, research based, international pharmaceutical company.

• Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries.

• Ranbaxy is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan. For more information, please visit www.ranbaxy.com.

• May 09 2014 Achieved sales guidance with Rs.130.4 Bn for the 15 months period ended March 2014

KEY HIGHLIGHTS/ DEVELOPMENTS

• Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Ranbaxy Laboratories Limited (“Ranbaxy”) announced their intent to merge in an all- stock transaction at a ratio of 0.8 shares of Sun for each Ranbaxy share. The transaction is expected to represent a tax-free exchange to Ranbaxy shareholders

• the Company has changed its accounting year from January-December (calendar year) to April-March (financial year). Thereby, the current accounting year is for a period of 15 months, i.e. January 2013- March 2014 and financials are not strictly comparable to the previous year, which was a 12 months period

• Established in 1995 with a capital of 50lakhs in New Delhi.•

• It is among the top 10 fastest growing Pharma companies of India as per ORG-IMS.•

• Mankind has out-performed the Indian Pharmaceutical industry by growing at the rate of 60% year after year.

6 DIVISIONS IN THE MANKIND

Discovery Mankind 

• - Incepted in the year 2002- Products for diabetic metabolic disorder. It is also having products in antibiotic, GI , anti fungal &lifestyle segments.

Vet Mankind

• - Division launched in the year 2007- It comprises veterinary products in Antibacterials ,Nutritionals, Reproductive, NSAIDs , Digestive categories etc.

Special Mankind -Launched in January 2007 is poised to meet OTC requirements.- premium category condoms, toothbrush, sanitarynapkins & sweeteners.

Magnet Labs

-Launched in the year 2007.-Acute & chronic 

Future Mankind -Positioned in the year 2007-orthopedic drugs along with GI & other specialty

Lifestar Pharma

-Launched in the year 2005-ophthalmic & Dermal products. It is also having product range in antibacterials, GI & other segments.

STRATEGY NO TARGET PRESSURE

TREMENDOUS WORK PRESSURE

MEET EACH AND EVERY DOCTOR 

SPECIAL CAMPAIGNS

HEAVY SAMPLING

FREQUENT GIFTING

HIGHEST NO. OF FIELD FORCE

ATTRACTIVE SCHEMES FOR MEDICAL STORES

ECONOMICAL PRODUCTS